Oragenics Inc. Overview
Oragenics, Inc., a development-stage biotechnology company based in Alachua, Florida, operates within the Health Care sector. The company is focused on developing medical products aimed at treating brain-related illnesses and diseases. Its primary areas of research include drug candidates for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC). Oragenics also boasts a proprietary powder formulation and an intranasal delivery device in its product portfolio. The company trades on the NYSE American exchange under the currency of USD.
Recent Financial Performance
As of the latest available data, Oragenics, Inc. closed at $0.19 USD. The company’s stock has experienced significant volatility over the past year. The 52-week high was recorded at $2.52 USD on August 12, 2024, while the 52-week low was $0.16 USD on May 6, 2025. This fluctuation highlights the challenges faced by development-stage biotech companies in maintaining investor confidence amid ongoing research and development efforts.
Valuation Metrics
Oragenics’ valuation metrics reveal a notable discrepancy. The price-to-earnings (P/E) ratio stands at -0.147402, reflecting the company’s current lack of profitability. Additionally, the price-to-book (P/B) ratio is 30.3, suggesting a significant gap between market valuation and book value. These figures underscore the speculative nature of investing in early-stage biotechnology firms, where future potential often outweighs current financial performance.
Market Position and Outlook
With a market capitalization of $4,170,000 USD, Oragenics remains a small player in the biotechnology industry. The company’s focus on niche medical conditions and innovative delivery methods positions it uniquely within the sector. However, the path to commercialization and regulatory approval remains uncertain, which continues to impact its stock performance.
For more detailed information, stakeholders and interested parties can visit Oragenics’ official website at www.oragenics.com .